Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
2026 January
  • Home
  • Archive for January, 2026
Watsnex Podcast
user

Host: Pascal Côté linkedin-img

user

Guest: Ross Youngs linkedin-img


×

AI, Microbiomes, & 8 Orders of Magnitude Improvement

  • January 29 2026
  • Video - Date: 01/26/2026
  • Length: 25:34 min

AI, Microbiomes, & 8 Orders of Magnitude Improvement

Summary – I recently sat down with Pascal Côté on the WATSNEX Podcast to discuss “AI, Microbiomes, and 8 Orders of Magnitude Improvement.” We dove deep into how industrial-scale microbiome mining and data depth are transforming biotech manufacturing and drug discovery. This conversation is part of the WATSNEX Podcast Founding Series, featuring leaders in biopharma and medtech. Watch the full episode here: https://youtu.be/16dg9QKOEcM

Reel1: https://youtube.com/shorts/tHsW1XkqEuw?feature=share

Reel2: https://youtube.com/shorts/AQhGTWx94EU?feature=share

Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo

  • January 27 2026

Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo (Jan 27, 2026) by Reuters. BERLIN, Jan 27 (Reuters) – Roche’s experimental obesity drug, which works in a similar way to Eli Lilly’s Zepbound, produced as much as 22.5% weight loss in a mid-stage trial, underpinning the Swiss drugmaker’s efforts to catch up with

Continue Reading

RSS Industry News

  • Intestinal interoceptive dysfunction drives age-associated cognitive decline March 11 2026
  • Memory loss is fuelled by gut microbes in ageing mice March 11 2026
  • Magnetoreception in a freshwater ciliate arises from endosymbiosis March 10 2026
  • Forget SkinTok: the real science of skincare and why it matters for your health March 10 2026
  • Microbiome signatures of mangroves and salt marsh halophyte rhizosphere soil sediments: a metagenomic approach March 8 2026
  • HIV-associated gut microbiome influences gut mucosal immunity March 6 2026
  • Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial March 4 2026
  • Microbiota-mediated induction of beige adipocytes in response to dietary cues March 4 2026
  • Microplastics and nanoplastics in the human gut: from signals to standards March 4 2026
  • Early-life immunological and microbial differences between East African and North European children March 3 2026
Quick Link
  • Products & Services
  • Blog
  • Contact
Recent Posts
  • Drug developer Generate Biomedicines raises $400 million in US IPO
  • Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics
  • AI, Microbiomes, & 8 Orders of Magnitude Improvement
Sign up for our newsletter
Loading
Biosortia Microbiomics © 2026. All Rights Reserved.